
Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
What this covers
This is a seven-minute solo walkthrough of a paper in Science on brain energy metabolism in Alzheimer's disease. The narrator, whom the transcript leaves unidentified, starts from the premise that the disease involves a chronic, progressive failure of energy handling in neurons and their support cells. The background is the astrocyte-to-neuron supply line: astrocytes turn glucose into lactate through glycolysis and pass it to neurons, and when that shuttle fails, neurons lose the energy they need to function. The paper's focus is IDO1 (indolamine 2,3-dioxygenase)), an enzyme that converts tryptophan into kynurenine (kyn)).
The evidence is laid out step by step. Amyloid and tau both raise IDO1 activity, kynurenine rises, and astrocyte glycolysis is suppressed. The pathway appeared in three independent animal models. In those models, inhibiting IDO1 restored lactate production, improved metabolic function, and improved memory and markers of learning such as long-term potentiation (LTP)). Astrocytes from patients with late-onset Alzheimer's show lower tryptophan and higher kynurenine, which suggests the same pathway runs in human disease. The narrator is plain that this has been replicated in human cells but not tested in living patients with Alzheimer's.
The practical turn is drug repurposing. A cancer drug, PF-06840003, targets IDO1, and the video raises the possibility of using it for Alzheimer's. It also speculates that the pathway's role in Parkinson's disease could make it relevant to other neurodegenerative conditions. The framing of Alzheimer's as a metabolic disease is flagged as contested.
The last section moves from the paper to four prevention habits: exercise, with its effect on BDNF; sleep of seven to nine hours for clearing metabolic debris; social connection and purpose; and fatty fish for long-chain omega-3s and possibly protective selenium. It also covers the more debated claim that carriers of the APOE4 allele may do better on a lower-carbohydrate, higher-fat diet, possibly but not necessarily a ketogenic diet.
Alzheimer's disease is fundamentally a metabolic disorder where amyloid and tau pathologies converge on the IDO1 enzyme to disrupt astrocyte lactate production, starving neurons of energy; inhibiting IDO1 restores brain metabolism and may be therapeutically tractable using existing cancer drugs.
- Classical Alzheimer's pathologies (amyloid and tau) both activate IDO1 enzyme in astrocytes, increasing kynurenine levels
- IDO1 activation inhibits astrocyte glycolysis and lactate transfer to neurons, causing neuronal energy starvation
- IDO1 inhibition in animal models and human cells restores lactate production, improves brain metabolic function, and enhances memory and learning markers
This asset isn't compiled yet
You're seeing its claims, ranked. Compile it to build the argument threads, weight them, and check each claim against your library — the full view.
Astrocytes support neurons by providing energy substrate to neurons in the form of the molecule lactate, converting glucose via glycolysis and fermentation into lactate which is then passed from astrocytes to neurons for energetic support.
“asites these are a type of gal support cell in the brain brain which support neurons and one way in which asites support neurons is by providing energy substrate to neurons in the form of the molecule lactate so simply asites turn glucose via glycolysis and fermentation into lactate and then the lactate can be passed from asites to neurons for energetic support”
Failure of the astrocyte-neuron lactate transport shuttle undermines neurons' ability to generate energy and undermines their ability to carry out critical neuronal functions.
“failure of this asite neuron lactate transport shuttle undermines neurons ability to generate energy and undermines their ability to carry out critical neuronal functions which is is simply put not good”
The effects of IDO1 inhibition on metabolic rescue are replicatable in human cells, though actual experiments in live humans with Alzheimer's disease have not yet been conducted.
“granted one can't actually do these particular experiments in live humans at least not yet although the effects were replicatable in human cells as far as metabolic rescue was concerned”
Alzheimer's disease is a metabolic disease characterized by dysfunctions in how brain cells (neurons) and astrocytes process and produce energy in the brain, and chronic progressive failure in brain energy metabolism can result in dementia including Alzheimer's disease.
“Alzheimer's disease is a metabolic disease characterized by dysfunctions in how brain cells neurons and their partner cells called asites process and produce energy in the brain and chronic progressive failure in brain energy metabolism can result in dementia including Alzheimer's disease”
IDO1 (indolamine 2,3-dioxygenase) is an enzyme that converts the amino acid tryptophan into a molecule called kynurenine (kyn).
“it's an enzyme called indolamine 23 dioxygenase or ido1 for short ido1 is an enzyme that converts the amino acid tryptophan into a molecule called curin or kyn for short”
Exercise is beneficial for brain health both through indirect effects on overall health and through direct effects where exercise increases levels of brain protective neurotrophic factors like BDNF (brain-derived neurotrophic factor).
“first exercise what's good for the body is good for the brain this is in part due to indirect effects of exercise and overall health but is also due to Direct effects whereby exercise can increase levels of certain brain protective neurotrophic factors like bdnf which support good brain health”
Adequate sleep of generally 7 to 9 hours is important for clearing metabolic debris out of the brain that has built up over the course of a day.
“get adequate sleep the amount needed varies from person to person but generally 7 to 9 hours is adequate for most sleep is really important for clearing the metabolic debris out of your brain the debris that built up over the course of a day”
Social connection and life purpose have powerful effects on lifespan and health span, making it important to enjoy life as part of Alzheimer's disease and dementia prevention.
“enjoy life while I'm by no means a socio neurobiologist it really appears that social connection and life purpose have powerful effects on lifespan and health span so don't forget to enjoy the ride it might just help you not forget”
Long-chain omega-3 fatty acids (EPA and DHA) consumed from fatty fish like salmon, mackerel, anchovy, and herring may provide neuroprotective benefits, potentially including the presence of neuroprotective forms of selenium in addition to the omega-3s themselves.
“get longchain omega-3 fatty acids in your diet EPA and DHA personally I like consuming these from fatty fish the smash fish salmon mackerel and chovy and hering you can get them from supplements as well but there may be benefits beyond the Omega-3s of actually eating real fatty fish and this includes the presence of certain potentially neuroprotective forms of selenium”
The classical amyloid and tau pathologies in Alzheimer's disease each converge on and increase the activity of the IDO1 enzyme, which increases kynurenine levels and thereby inhibits astrocyte glycolysis, decreasing lactate transfer to neurons and starving neurons of energy.
“what researchers of the study find is that the classical ameloid and to pathologies and Alzheimer's disease each Converge on and increase the activity of the ido1 enzyme which inre increases kyn levels thereby inhibiting asroy glycolysis decreasing lactate transfer to neurons starving neurons of energy”
For individuals with the APOE4 risk allele for Alzheimer's disease, the literature suggests that eating a lower carbohydrate, higher fat diet, and potentially a ketogenic diet (though not necessarily), might be particularly beneficial.
“for those specifically with the Appo E4 risk a Leal for Alzheimer's disease the literature continues to suggest eating a lower carb higher fat and potentially ketogenic although not necessarily diet might be particularly beneficial”
Human astrocytes from patients with late-onset Alzheimer's disease have lower tryptophan levels and higher kynurenine levels, demonstrating that the IDO1-kynurenine pathway is active in the human Alzheimer's brain.
“human astrocytes from patients with the most common form of Alzheimer's disease late onset Alzheimer's disease also had lower tryptophan and higher kyn levels and that inhibiting id1 normal aliz these levels basically revealing that this pathway is active in the human Alzheimer's brain as well”
The IDO1-kynurenine pathway was found to be relevant in three independent animal models of Alzheimer's disease and has parallels in human brains and human brain cells.
“impressively in this paper they found that this pathway was relevant in three independent animal models of Alzheimer's and has parallels in human brains in human brain cells where human astrocytes from patients with the most common form of Alzheimer's disease late onset Alzheimer's disease also had lower tryptophan and higher kyn levels”
Inhibiting IDO1 restores astrocyte glycolysis and lactate production, improves metabolic function in the brain, improves neuronal function and markers of neuronal learning like long-term potentiation, and improves memory in animal models.
“they found that inhibiting ido1 restored astroy glycolysis and lactate production it improved metabolic function in the brain improved neur neon Al function and markers functional markers of learning like long-term potentiation and improved memory and these effects were replicatable across models”
The IDO1-kynurenine pathway is also involved in other forms of neurodegenerative diseases like Parkinson's disease, leading to the possibility that targeting this pathway could have positive effects on dementia and neurodegenerative diseases beyond just Alzheimer's disease.
“once's more the id1 kyn pathway is also involved in other forms of neurodegenerative diseases like Parkinson's disease leading to the possibility that targeting this pathway could have positive effects on dementia and neurodegenerative diseases Beyond just Alzheimer's”
There exists a cancer drug named PF-06840003 that targets IDO1, raising the possibility of repurposing this cancer metabolism therapy for Alzheimer's disease treatment in live humans.
“the answer is there's actually already cancer drug that targets ido1 uncreative named pf68 in this paper but this raises the possibility of repurposing a cancer metabolism therapy for Alzheimer's disease”